President & CEO, RainDance Technologies
Roopom Banerjee is President and CEO of RainDance Technologies. Previously, he held positions at Leerink Swann, McKinsey & Company and Goldman Sachs advising Fortune 500 healthcare companies on corporate and growth strategies. He’s completed over 50 transactions, including IPOs, private placements and mergers and acquisitions. Prior he was a cancer and genomics research scientist at Dana Farber Cancer Institute, Whitehead Institute/M.I.T. Human Genome Project, and Massachusetts General Hospital Cancer Center.
Liquid Biopsy: Why Technology Matters for Commercialization and Adoption
Demand for liquid biopsy is expected to reach $20 billion a year within five years from about $100 million today, according to industry analysts. What will separate the truly meaningful tests and applications from the inconclusive and confounding? What has early development taught us about which diseases are most likely to benefit from liquid biopsy and why?